Form 4: Cero Therapeutics Holdings, Inc. Officer Kristen Pierce Acquires Stock Options

Kristen Pierce, Chief Development Officer of Cero Therapeutics Holdings, Inc., acquired stock options for 200,000 shares on October 1, 2024.

Summary

• On October 1, 2024, Kristen Pierce, the Chief Development Officer of Cero Therapeutics Holdings, Inc., acquired stock options for 200,000 shares of common stock.
• The options have an exercise price of $0.10 per share.
• The options vest in 24 monthly installments, contingent upon continued service, and expire on September 30, 2034.
• Following the transaction, Pierce directly owns derivative securities for 200,000 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to an officer. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of stock options by a key officer may indicate confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for company officers to receive stock options as part of their compensation.

Stakeholder Impact

• The acquisition of stock options by an officer could be viewed positively by shareholders as it aligns the officer's interests with the company's success.

Key Dates

Keywords

Stock Options, Form 4, Officer, CERO, Cero Therapeutics Holdings, Inc., Beneficial Ownership